TCR2 THERAPEUTICS INC (TCRR) Stock News

USA - NASDAQ:TCRR - US87808K1060 - Common Stock

1.48 USD

-0.09 (-5.73%)

Last: 5/31/2023, 8:00:02 PM

1.53 USD

+0.05 (+3.38%)

After Hours: 5/31/2023, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TCRR Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Seeking Alpha - Mentions: ADAP

Adaptimmune completes merger with fellow immunology company TCR2 (ADAP)

3 years ago - By: Benzinga - Mentions: ESPR SRTS

Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying

3 years ago - By: Benzinga

Recap: TCR2 Therapeutics Q1 Earnings

3 years ago - By: TCR2 Therapeutics

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

3 years ago - By: TCR2 Therapeutics

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 years ago - By: Research and Markets

Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs

3 years ago - By: InvestorPlace - Mentions: ADAP

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

3 years ago - By: Kahn Swick & Foti, LLC

TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR

3 years ago - By: TCR2 Therapeutics

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 years ago - By: TCR2 Therapeutics

TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

3 years ago - By: Kahn Swick & Foti, LLC

TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR

3 years ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune

3 years ago - By: Halper Sadeh LLC

TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders